Fred Hutchinson spin-out Adaptive Biotechnologies raises $195m for immunotherapy treatments.

Adaptive Biotechnologies, a life sciences firm developing immunotherapy treatments, has raised $195m in its series F round. Adaptive has now raised $401.5m in venture backing. The latest round was backed by new investors Rock Springs Capital, Tiger Management Corporation, Senator Investment Group, and Matrix Capital. Viking Global, which backed Adaptive’s 2014 $105m venture round, also joined the round, as did fellow existing backers Casdin Capital and Alexandria Real Estate Equities. The Seattle-based firm is founded on intellectual property from the Fred Hutchinson Cancer Research Centre, one of three research institutes behind fellow immunotherapy firm Juno Therapeutics which raised $316m in venture backing last year before capping 2014 off with a $280m IPO. The company is developing next generation sequencing of T and B cell receptors in the immune system, and plans to deploy its immunosequencing platform against cancer and immune-mediated diseases. Chad Robins, CEO and co-founder of Adaptive, said: “The disruptive potential of our ground-breaking immunosequencing technology is evidenced by the tremendous commitment of our world-class investors. We are honoured to work with a consortium of investors who share in our vision that understanding the adaptive immune system will change the course of medicine across many therapeutic areas including cancer and other immune-mediated diseases.”

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?